Scharf · Environmental microbiology 2016 · narrative review · n=?

Gliotoxin--bane or boon?

Cited 128 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review synthesizing fungal biology, ecology, and preclinical data without original human trial evidence.

PubMed 26443473 · doi:10.1111/1462-2920.13080 · record verified 2026-08-27

What was done

This narrative review synthesized literature on the fungal metabolite gliotoxin (GT), examining its ecological role as a defensive molecule, its use in Trichoderma-based agricultural biocontrol, its therapeutic properties (immunosuppressive and anti-tumour), and its function as a virulence determinant in human Aspergillus fumigatus infections.

What was found

The abstract reports no quantitative metrics or numerical findings. It qualitatively characterizes gliotoxin as a multifunctional molecule acting as an antibiotic against plant pathogens, a human pathogenicity determinant, a candidate diagnostic marker, and a commercial biofungicide component.

Why it matters

Understanding the dual nature of gliotoxin helps balance its beneficial applications in crop protection and pharmacology against its pathogenicity risks in human fungal infections.

Limits

The review relies on qualitative synthesis without systematic review methodology, quantitative data extraction, or human clinical trial results. No specific experimental metrics or sample sizes are detailed in the abstract.

Cited by